At BioNxt, our science is focused on revolutionizing drug delivery to address unmet needs in chronic and neurodegenerative care. Leveraging advanced sublingual thin-film (ODF) and transdermal skin-patch technologies, we provide patient-centric solutions that enhance bioavailability, improve dosing accuracy, and increase compliance—especially for patients with swallowing difficulties or who require precision dosing.
Our sublingual thin-film technology enables rapid absorption through the oral mucosa, bypassing the gastrointestinal tract and liver metabolism for a faster and more consistent therapeutic effect. This approach is ideal for patients who require fast-acting relief or struggle with traditional oral medications, offering them a discreet, convenient option that enhances patient experience and adherence. Meanwhile, our transdermal patches deliver medications steadily through the skin, providing sustained drug release that reduces dosing frequency, improves stability, and minimizes peak-related side effects. These innovations are especially valuable for patients with chronic or degenerative conditions who rely on long-term medication.
Intellectual Property and Patent Portfolio
BioNxt’s commitment to innovation is backed by a robust intellectual property framework that secures our proprietary technologies in key global markets. Our recent patents cover sublingual drug formulations, particularly for chemotherapy and autoimmune neurological conditions, establishing BioNxt as a leader in high-barrier-to-entry fields. Our flagship patent, “Sublingual Formulation of Anticancer Compounds for the Treatment of Autoimmune Neurodegenerative Diseases,” received a positive International Search Report (ISR) from the European Patent Office in Q3 2024. This recognition of the novelty, inventive step, and practical utility of our technology reinforces our patent’s strength and broad coverage across critical markets.
As part of our IP strategy, we are actively pursuing nationalization of our patents in high-value regions, including the EU, US, Canada, Australia, New Zealand, Israel, MENA, and China. This extensive IP protection framework provides BioNxt with a significant competitive advantage, ensuring exclusivity and reducing the threat of generic competition.
Accelerated Development Pathway
In addition to our strong IP foundation, BioNxt leverages approved active pharmaceutical ingredients (APIs) to streamline our regulatory pathway. By utilizing bioequivalence studies, we can expedite time-to-market, significantly reducing development costs and regulatory hurdles. This approach allows BioNxt to bring innovative therapies to patients faster, with a clear focus on safety and efficacy.
At BioNxt, our dedication to advancing drug delivery science is fueled by a commitment to improving patients’ quality of life. By combining breakthrough technologies, a strategic patent portfolio, and an accelerated development process, we are positioned to set new standards in patient-centered therapeutics for chronic and neurodegenerative conditions worldwide.
Be in the know. Get our press releases and latest news first.
Hear about our latest research, products, exclusive partnerships & more.